“Controversial Alzheimer’s Drug Wins FDA Approval,” by Judy George, MedPageToday

Quote:  “The controversial Alzheimer’s treatment aducanumab (Aduhelm) won FDA approval Monday using the accelerated approval pathway. Under this pathway, the agency approves a drug for a serious or life-threatening illness that may provide meaningful therapeutic benefit over existing treatments when the drug is shown to have an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients and there remains some uncertainty about the drug’s clinical benefit.”

LTC Comment, Stephen A. Moses, President, Center for Long-Term Care Reform:

Kind of a stretch.

 

 

 

 

 

Subscribe to GoldenCare News